Microdose: Federal psychedelics efforts remain stagnant | Cannabis Law Report | How to order Skittles Moonrock online

Federal psychedelics efforts remain stagnant

When President Trump took office in 2025, some psychedelics advocates were excited about the cabinet he selected that appeared poised to fast-track psychedelics through federal approvals; Health and Human Services Secretary Robert F. Kennedy Jr. said in July that psychedelics would be available within 12 months. Now, more than a year into Trump’s presidency, a trio of recent articles give us a glimpse into what advocates see as a lack of strategy at the federal level regarding psychedelics.

• Psychedelic executives and advocacy groups tell POLITICO they’re disappointed they’ve not seen any progress. “A year into his tenure, Robert F. Kennedy Jr. has yet to expand access to the mind-altering drugs and advocates are starting to lose patience,” journalist Amanda Chu reports.
• Lawmakers are trying to pressure the administration to take action. Two weeks ago, The Mission Within, a veterans psychedelic group, and advocacy group Psychedelic Medicine Coalition, held a forum to advocate for veterans’ access to psychedelics. U.S. Representatives Lou Correa (D-CA), Jack Bergman (R-MI), and Morgan Luttrell (R-TX), all part of the Congressional Psychedelics Advancing Therapies (PATH) Caucus, also joined them. Marijuana Moment reported that Luttrell warned that even a single misstep could jeopardize the movement; Bergman agreed that other members of congress were “risk-averse” about the issue.
• While psychedelics may not be gaining much traction at the federal legislative or agency policy level, FDA Division of Psychiatry Director Tiffany Farchione recently revealed there’s been a glut of psychedelics drug applications. Psychedelic Alpha reports that Farcione spoke at a webinar held by the American Brain Coalition and said that “fully a third of my workload” was reviewing psychedelic investigational new drug applications. Farchione said that the eventual goal was to approve psychedelics so “folks won’t have to go on a retreat in another country to receive these medications.” National Institute on Drug Abuse director Nora Volkow, who also recently penned a blog post on the drugs’ promise, writing that they “represent a potential paradigm shift” in the treatment of mental health conditions.

Source Microdose

Get Connected